Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study

M. White; S. Yusuf; R. S. McKelvie; D. Pericak; J. Young; R. Latini; J. Pogue; R. J. Burns; J. Probstfield; R. T. Tsuyuki; A. P. Maggioni; Jr Avezum A.; J. L. Rouleau

Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study

M. White, S. Yusuf, R. S. McKelvie, D. Pericak, J. Young, R. Latini, J. Pogue, R. J. Burns, J. Probstfield, R. T. Tsuyuki, A. P. Maggioni, Jr Avezum A., J. L. Rouleau

Istituto di Ricerche Farmacologiche "Mario Negri"

Research output: Contribution to journal › Article › peer-review

Abstract

Background - Metoprolol provides clinical benefits in patients with congestive heart failure (CHF). In this study, we investigated the effects of controlled-release metoprolol (metoprolol CR) on clinical status, on left ventricular (LV) volumes and function, and on neurohumoral activation in a large number of patients with CHF of mixed causes. Methods and Results - Four hundred twenty-six patients with symptomatic CHF were randomized to receive metoprolol CR or placebo for 24 weeks. Metoprolol CR did not affect 6-minute walk distance, New York Heart Association functional class, or quality of life. However, there was a significant improvement in measures of LV function with an attenuation in the increase in LV end-diastolic (+23±65 mL [placebo] versus +6±61 mL, P=0.01) and LV end-systolic (+19±55 mL [placebo] versus - 2±51 mL, P

Original language	English
Pages (from-to)	378-384
Number of pages	7
Journal	Circulation
Volume	101
Issue number	4
Publication status	Published - Feb 1 2000

Keywords

Heart failure
Hormones
Receptors, adrenergic, beta
Ventricles

ASJC Scopus subject areas

Physiology
Cardiology and Cardiovascular Medicine

Cite this

White, M., Yusuf, S., McKelvie, R. S., Pericak, D., Young, J., Latini, R., Pogue, J., Burns, R. J., Probstfield, J., Tsuyuki, R. T., Maggioni, A. P., Avezum A., J., & Rouleau, J. L. (2000). Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation, 101(4), 378-384.

White, M, Yusuf, S, McKelvie, RS, Pericak, D, Young, J, Latini, R, Pogue, J, Burns, RJ, Probstfield, J, Tsuyuki, RT, Maggioni, AP, Avezum A., J & Rouleau, JL 2000, 'Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study', Circulation, vol. 101, no. 4, pp. 378-384.

@article{4e33b364918f41bdbb7862e81a4e6be5,

title = "Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study",

abstract = "Background - Metoprolol provides clinical benefits in patients with congestive heart failure (CHF). In this study, we investigated the effects of controlled-release metoprolol (metoprolol CR) on clinical status, on left ventricular (LV) volumes and function, and on neurohumoral activation in a large number of patients with CHF of mixed causes. Methods and Results - Four hundred twenty-six patients with symptomatic CHF were randomized to receive metoprolol CR or placebo for 24 weeks. Metoprolol CR did not affect 6-minute walk distance, New York Heart Association functional class, or quality of life. However, there was a significant improvement in measures of LV function with an attenuation in the increase in LV end-diastolic (+23±65 mL [placebo] versus +6±61 mL, P=0.01) and LV end-systolic (+19±55 mL [placebo] versus - 2±51 mL, P",

keywords = "Heart failure, Hormones, Receptors, adrenergic, beta, Ventricles",

author = "M. White and S. Yusuf and McKelvie, {R. S.} and D. Pericak and J. Young and R. Latini and J. Pogue and Burns, {R. J.} and J. Probstfield and Tsuyuki, {R. T.} and Maggioni, {A. P.} and {Avezum A.}, Jr and Rouleau, {J. L.}",

year = "2000",

month = feb,

day = "1",

language = "English",

volume = "101",

pages = "378--384",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy

T2 - The randomized evaluation of strategies for left ventricular dysfunction pilot study

AU - White, M.

AU - Yusuf, S.

AU - McKelvie, R. S.

AU - Pericak, D.

AU - Young, J.

AU - Latini, R.

AU - Pogue, J.

AU - Burns, R. J.

AU - Probstfield, J.

AU - Tsuyuki, R. T.

AU - Maggioni, A. P.

AU - Avezum A., Jr

AU - Rouleau, J. L.

PY - 2000/2/1

Y1 - 2000/2/1

N2 - Background - Metoprolol provides clinical benefits in patients with congestive heart failure (CHF). In this study, we investigated the effects of controlled-release metoprolol (metoprolol CR) on clinical status, on left ventricular (LV) volumes and function, and on neurohumoral activation in a large number of patients with CHF of mixed causes. Methods and Results - Four hundred twenty-six patients with symptomatic CHF were randomized to receive metoprolol CR or placebo for 24 weeks. Metoprolol CR did not affect 6-minute walk distance, New York Heart Association functional class, or quality of life. However, there was a significant improvement in measures of LV function with an attenuation in the increase in LV end-diastolic (+23±65 mL [placebo] versus +6±61 mL, P=0.01) and LV end-systolic (+19±55 mL [placebo] versus - 2±51 mL, P

AB - Background - Metoprolol provides clinical benefits in patients with congestive heart failure (CHF). In this study, we investigated the effects of controlled-release metoprolol (metoprolol CR) on clinical status, on left ventricular (LV) volumes and function, and on neurohumoral activation in a large number of patients with CHF of mixed causes. Methods and Results - Four hundred twenty-six patients with symptomatic CHF were randomized to receive metoprolol CR or placebo for 24 weeks. Metoprolol CR did not affect 6-minute walk distance, New York Heart Association functional class, or quality of life. However, there was a significant improvement in measures of LV function with an attenuation in the increase in LV end-diastolic (+23±65 mL [placebo] versus +6±61 mL, P=0.01) and LV end-systolic (+19±55 mL [placebo] versus - 2±51 mL, P

KW - Heart failure

KW - Hormones

KW - Receptors, adrenergic, beta

KW - Ventricles

UR - http://www.scopus.com/inward/record.url?scp=0034142256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034142256&partnerID=8YFLogxK

M3 - Article

C2 - 10653828

AN - SCOPUS:0034142256

VL - 101

SP - 378

EP - 384

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -

Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: The randomized evaluation of strategies for left ventricular dysfunction pilot study

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this